Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25C | P30307 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382846 | 0.88 | HPGD (0.37) | F2RL3MEN1KMT2ANPC1LMNA | |
| SCHEMBL1339108 | 0.87 | PIM1 (0.40) | F2RL3HSD11B1MEN1KMT2ALMNA | |
| SCHEMBL2386231 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1338067 | 0.85 | KDM4E (0.48) | F2RL3HSD11B1MEN1KMT2ALMNA | |
| SCHEMBL2384546 | 0.85 | ALDH1A1 (0.41) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1338853 | 0.84 | CNR1 (0.41) | F2RL3CA9CA12CNR1CNR2 | |
| SCHEMBL1340487 | 0.84 | KDM4E (0.43) | F2RL3MEN1KMT2ALMNAGAA | |
| SCHEMBL3443977 | 0.82 | ACHE (0.48) | MEN1KMT2AGAAHPGDKDM4E | |
| SCHEMBL3443888 | 0.82 | CYP2A6 (0.39) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1337089 | 0.82 | JAK2 (0.39) | F2RL3HSD11B1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012991-B2 | 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate | SANOFI-AVENTIS (FR) | 2011-09-06 | — | — | US | claimed |
| WO-2010138661-A1 | NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2010-12-02 | — | — | WO | claimed |
| WO-2010138660-A1 | ANTICANCER PHARMACEUTICAL FORMULATION | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | WO | claimed |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | claimed |
| US-7390818-B2 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-06-24 | — | — | US | claimed |
| EP-1556382-B1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | claimed |
| EP-1556382-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041817-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-05-21 | — | — | WO | claimed |
| US-8012991-B2 | 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate | SANOFI-AVENTIS (FR) | 2011-09-06 | — | — | US | disclosed |
| WO-2010138661-A8 | NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010138661-A1 | NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138661-A1 | NANOPARTICULATE ANTICANCER COMPOSITIONS AND METHODS FOR MAKING THE SAME | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138660-A1 | ANTICANCER PHARMACEUTICAL FORMULATION | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138660-A1 | ANTICANCER PHARMACEUTICAL FORMULATION | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138660-A1 | ANTICANCER PHARMACEUTICAL FORMULATION | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | WO | disclosed |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-7390818-B2 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-06-24 | — | — | US | disclosed |
| EP-1556382-B1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | PNPO, PDXK, PLPBP | F2RL3 1153/4885HSD11B1 1013/4885MEN1 1598/4885 |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | PNPO, PLPBP, DPYD | F2RL3 1768/4885HSD11B1 1043/4885MEN1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.